InvestorsHub Logo
Followers 0
Posts 185
Boards Moderated 0
Alias Born 07/02/2007

Re: BonelessCat post# 7473

Monday, 10/15/2007 9:54:47 AM

Monday, October 15, 2007 9:54:47 AM

Post# of 146240
The burn rate is huge. They have paid over $1 million to Diwan alone (TheraCour) for "licensing fees" and other costs. Not to mention the consulting fees, the PR costs to pump the company through podcasts, etc. Over $6 million total so far during the "development stage" with no products to show for it.

All that money, and they are filing the 10-K late.

To cover these costs, they have had to issue millions of shares at cut rate prices. As these shares get sold, the stock price keeps getting hammered lower and lower.

I don't get it. Since NNVC doesn't actually own any of the technology, why didn't Diwan just take Theracour public? How "frugal" is it to run two different companies, when one would have sufficed?

We get talk here sometimes of "big pharma" buying out Nanoviricides, but there's nothing to buy.





Hype is a dangerous tool in the wrong hands.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NNVC News